Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22
Wedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the price target from $15 to $22.
Benzinga23 days agoZURA
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20
Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price target from $15 to $20.
Benzinga23 days agoZURA
Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 23.53 percent decrease over losses of $(0.17) per share from the same
Benzinga24 days agoZURA